The presence of NAFLD/NASH, otherwise known as MAFLD, has proven to be a significant marker of progressive liver disease and virologic response to HCV treatment, where the severity and frequency is significantly greater in G-3, while G-1 is associated with a poor response to both IFN-based and IFN-free DAA therapy. The gene discussed is IFNA1; the disease is liver disorder.